JP6276760B2 - ４−アルキニルイミダゾール誘導体およびそれを有効成分として含有する医薬 - Google Patents
４−アルキニルイミダゾール誘導体およびそれを有効成分として含有する医薬 Download PDFInfo
- Publication number
- JP6276760B2 JP6276760B2 JP2015522867A JP2015522867A JP6276760B2 JP 6276760 B2 JP6276760 B2 JP 6276760B2 JP 2015522867 A JP2015522867 A JP 2015522867A JP 2015522867 A JP2015522867 A JP 2015522867A JP 6276760 B2 JP6276760 B2 JP 6276760B2
- Authority
- JP
- Japan
- Prior art keywords
- group
- compound
- mmol
- methyl
- general formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013123968 | 2013-06-12 | ||
| JP2013123968 | 2013-06-12 | ||
| PCT/JP2014/065643 WO2014200075A1 (ja) | 2013-06-12 | 2014-06-12 | ４－アルキニルイミダゾール誘導体およびそれを有効成分として含有する医薬 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPWO2014200075A1 JPWO2014200075A1 (ja) | 2017-02-23 |
| JP6276760B2 true JP6276760B2 (ja) | 2018-02-07 |
Family
ID=52022361
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015522867A Active JP6276760B2 (ja) | 2013-06-12 | 2014-06-12 | ４−アルキニルイミダゾール誘導体およびそれを有効成分として含有する医薬 |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US9593081B2 (enExample) |
| EP (1) | EP3009426B1 (enExample) |
| JP (1) | JP6276760B2 (enExample) |
| KR (1) | KR102212981B1 (enExample) |
| CN (1) | CN105431416B (enExample) |
| AU (1) | AU2014279113B2 (enExample) |
| BR (1) | BR112015030315B1 (enExample) |
| CA (1) | CA2914997C (enExample) |
| DK (1) | DK3009426T3 (enExample) |
| ES (1) | ES2669977T3 (enExample) |
| HR (1) | HRP20180703T1 (enExample) |
| HU (1) | HUE039015T2 (enExample) |
| IL (1) | IL242912A0 (enExample) |
| LT (1) | LT3009426T (enExample) |
| MX (1) | MX369804B (enExample) |
| MY (1) | MY168609A (enExample) |
| NO (1) | NO3009426T3 (enExample) |
| NZ (1) | NZ715837A (enExample) |
| PH (1) | PH12015502745B1 (enExample) |
| PL (1) | PL3009426T3 (enExample) |
| PT (1) | PT3009426T (enExample) |
| RS (1) | RS57406B1 (enExample) |
| RU (1) | RU2662806C2 (enExample) |
| SG (1) | SG11201510121RA (enExample) |
| SI (1) | SI3009426T1 (enExample) |
| TR (1) | TR201807659T4 (enExample) |
| WO (1) | WO2014200075A1 (enExample) |
| ZA (1) | ZA201600135B (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO3009426T3 (enExample) * | 2013-06-12 | 2018-09-29 | ||
| CR20180323A (es) | 2015-11-20 | 2018-08-06 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituídos como moduladores de los receptores de pge2 |
| EP3541801A4 (en) * | 2016-11-18 | 2020-04-29 | Dow AgroSciences LLC | 4- (6- (2- (2,4-DIFLUORPHENYL) -1,1-DIFLUOR-2-HYDROXY-3- (5-MERCAPTO-1H |
| EP3625223B1 (en) | 2017-05-18 | 2021-08-11 | Idorsia Pharmaceuticals Ltd | Pyrimidine derivatives |
| JP7159214B2 (ja) | 2017-05-18 | 2022-10-24 | イドーシア ファーマシューティカルズ リミテッド | Ｐｇｅ２レセプター調節剤としてのフェニル誘導体 |
| BR112019024114A2 (pt) | 2017-05-18 | 2020-06-02 | Idorsia Pharmaceuticals Ltd | Composto, e, métodos de modulação de uma resposta imune e de profilaxia ou tratamento de uma condição |
| JP7159215B2 (ja) | 2017-05-18 | 2022-10-24 | イドーシア ファーマシューティカルズ リミテッド | Ｐｇｅ２レセプター調節剤としてのピリミジン誘導体 |
| TW201900179A (zh) | 2017-05-18 | 2019-01-01 | 瑞士商愛杜西亞製藥有限公司 | 作為pge2受體調節劑之苯并呋喃及苯并噻吩衍生物 |
| US11479550B2 (en) | 2017-05-22 | 2022-10-25 | Ono Pharmaceutical Co., Ltd. | EP4 antagonist |
| JP2020142989A (ja) * | 2017-06-21 | 2020-09-10 | Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 | イミダゾール誘導体及びそれを含有する医薬 |
| CN117643587A (zh) * | 2018-02-05 | 2024-03-05 | 深圳市原力生命科学有限公司 | 用于治疗癌症的杂二环羧酸 |
| CN108997252B (zh) * | 2018-07-27 | 2020-04-28 | 常州大学 | 一种恶二唑衍生物的绿色合成方法 |
| US20230390303A1 (en) | 2020-11-13 | 2023-12-07 | Ono Pharmaceutical Co., Ltd. | Cancer treatment by combination of ep4 antagonist and immune checkpoint inhibitor |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1489588A (zh) * | 2001-01-31 | 2004-04-14 | �Ʒ� | 用作pde4同功酶抑制剂的噻唑基,噁唑基,吡咯基,和咪唑基羧酸酰胺衍生物 |
| RU2315746C2 (ru) * | 2001-08-09 | 2008-01-27 | Оно Фармасьютикал Ко., Лтд. | Производные карбоновых кислот и фармацевтическое средство, содержащее их в качестве активного ингредиента |
| US20040023853A1 (en) | 2002-05-23 | 2004-02-05 | Peri Krishna G. | Antagonistic peptides of prostaglandin E2 receptor subtype EP4 |
| AP2006003534A0 (en) | 2003-09-03 | 2006-04-30 | Pfizer | Phenyl or pyridyl amide compounds as prostaglandin E2 antagonists. |
| DE602005015215D1 (de) | 2004-05-04 | 2009-08-13 | Raqualia Pharma Inc | Orthosubstituierte aryl- oder heteroarylamidverbindungen |
| MXPA06011555A (es) | 2004-05-04 | 2006-12-15 | Pfizer | Compuestos de metil-aril o heteroaril-amida sustituida. |
| WO2006087355A1 (en) * | 2005-02-16 | 2006-08-24 | Solvay Pharmaceuticals B.V. | 1h-imidiazole derivatives as cannabinoid cb2 receptor modulators |
| CA2648729A1 (en) | 2006-04-24 | 2007-11-01 | Merck Frosst Canada Ltd. | Indole amide derivatives as ep4 receptor antagonists |
| CA2654811A1 (en) | 2006-06-12 | 2007-12-21 | Merck Frosst Canada Ltd. | Indoline amide derivatives as ep4 receptor ligands |
| WO2008017164A1 (en) | 2006-08-11 | 2008-02-14 | Merck Frosst Canada Ltd. | Thiophenecarboxamide derivatives as ep4 receptor ligands |
| EP2114877B1 (en) * | 2007-02-26 | 2012-12-26 | Merck Canada Inc. | Indole and indoline cyclopropyl amide derivatives as ep4 receptor antagonists |
| BRPI0814403A2 (pt) * | 2007-07-02 | 2015-01-27 | Hoffmann La Roche | Devirados de imidazol como antagonistas de receptor ccr2 |
| EP2460787A1 (en) | 2007-07-03 | 2012-06-06 | Astellas Pharma Inc. | Amide compounds and their use as PGE2 antagonists. |
| CN102026961B (zh) | 2008-05-14 | 2014-04-09 | 安斯泰来制药株式会社 | 酰胺化合物 |
| US8404736B2 (en) | 2008-08-14 | 2013-03-26 | Beta Pharma Canada Inc. | Heterocyclic amide derivatives as EP4 receptor antagonists |
| CA2806121C (en) * | 2010-09-21 | 2018-10-09 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition |
| US8828987B2 (en) | 2010-12-10 | 2014-09-09 | Rottapharm Biotech S.R.L. | Pyridine amide derivatives as EP4 receptor antagonists |
| WO2012103071A2 (en) | 2011-01-25 | 2012-08-02 | Eisai R&D Management Co., Ltd. | Compounds and compositions |
| US9181279B2 (en) | 2011-07-04 | 2015-11-10 | Rottapharm Biotech S.R.L. | Cyclic amine derivatives as EP4 receptor antagonists |
| NO3009426T3 (enExample) * | 2013-06-12 | 2018-09-29 |
-
2014
- 2014-06-12 NO NO14811154A patent/NO3009426T3/no unknown
- 2014-06-12 JP JP2015522867A patent/JP6276760B2/ja active Active
- 2014-06-12 MX MX2015017161A patent/MX369804B/es active IP Right Grant
- 2014-06-12 MY MYPI2015704535A patent/MY168609A/en unknown
- 2014-06-12 TR TR2018/07659T patent/TR201807659T4/tr unknown
- 2014-06-12 LT LTEP14811154.5T patent/LT3009426T/lt unknown
- 2014-06-12 ES ES14811154.5T patent/ES2669977T3/es active Active
- 2014-06-12 PT PT148111545T patent/PT3009426T/pt unknown
- 2014-06-12 SI SI201430707T patent/SI3009426T1/en unknown
- 2014-06-12 CA CA2914997A patent/CA2914997C/en active Active
- 2014-06-12 US US14/897,324 patent/US9593081B2/en active Active
- 2014-06-12 RS RS20180743A patent/RS57406B1/sr unknown
- 2014-06-12 AU AU2014279113A patent/AU2014279113B2/en active Active
- 2014-06-12 RU RU2015155585A patent/RU2662806C2/ru active
- 2014-06-12 KR KR1020167000476A patent/KR102212981B1/ko active Active
- 2014-06-12 WO PCT/JP2014/065643 patent/WO2014200075A1/ja not_active Ceased
- 2014-06-12 CN CN201480044505.6A patent/CN105431416B/zh active Active
- 2014-06-12 HR HRP20180703TT patent/HRP20180703T1/hr unknown
- 2014-06-12 HU HUE14811154A patent/HUE039015T2/hu unknown
- 2014-06-12 SG SG11201510121RA patent/SG11201510121RA/en unknown
- 2014-06-12 BR BR112015030315-3A patent/BR112015030315B1/pt active IP Right Grant
- 2014-06-12 EP EP14811154.5A patent/EP3009426B1/en active Active
- 2014-06-12 NZ NZ715837A patent/NZ715837A/en unknown
- 2014-06-12 DK DK14811154.5T patent/DK3009426T3/en active
- 2014-06-12 PL PL14811154T patent/PL3009426T3/pl unknown
-
2015
- 2015-12-03 IL IL242912A patent/IL242912A0/en active IP Right Grant
- 2015-12-09 PH PH12015502745A patent/PH12015502745B1/en unknown
-
2016
- 2016-01-07 ZA ZA2016/00135A patent/ZA201600135B/en unknown
-
2017
- 2017-01-24 US US15/414,200 patent/US9855257B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6276760B2 (ja) | ４−アルキニルイミダゾール誘導体およびそれを有効成分として含有する医薬 | |
| RU2518073C2 (ru) | Новое бициклическое гетероциклическое соединение | |
| JP4629036B2 (ja) | アリールアルキルアミン化合物及びその製法 | |
| US8815903B2 (en) | Indole derivative and pharmacologically acceptable salt thereof | |
| US8796247B2 (en) | Indole derivative, and pharmacologically acceptable salt thereof | |
| CA2730793C (en) | Azole compound | |
| CN102239164A (zh) | 2h-色烯化合物及其衍生物 | |
| WO2011099832A2 (en) | Novel benzimidazole compound, preparation method thereof and pharmaceutical composition comprising the same | |
| WO1991019697A1 (fr) | Derive de pyridine avec antagonisme de l'angiotensine ii | |
| CA2825746A1 (en) | Pyrazolopyridine derivative or pharmacologically acceptable salt thereof | |
| EA034201B1 (ru) | Соединения в качестве модуляторов ror-гамма | |
| GB2513403A (en) | WNT pathway modulators | |
| TW201245187A (en) | Pyrazole derivatives | |
| WO2007004733A1 (ja) | ペルオキシソーム増殖剤活性化受容体δの活性化剤 | |
| HK1221215B (zh) | 4-炔基咪唑衍生物和含有其作为有效成分的药物 | |
| JPWO2010113952A1 (ja) | ムスカリン受容体拮抗薬 | |
| WO2001064641A1 (en) | Hydroxyethoxybenzamide derivatives and drugs containing the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170317 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170926 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20171117 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20171214 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180112 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6276760 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |